ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Weaver, David A ^a   Crawford, Erin L ^a   Warner, Kristy A ^a   Elkhairi, Fadel ^a   Khuder, Sadik A ^a   Willey, James C ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER C1; ABC TRANSPORTER C10; ABC TRANSPORTER C4; BETA ACTIN; CARRIER PROTEIN; CISPLATIN; DNA DAMAGE INDUCIBLE TRANSCRIPT PROTEIN 3; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 3; GENERAL TRANSCRIPTION FACTOR IIH; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 5; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG; X RAY REPAIR COMPLEMENTING DEFECTIVE REPAIR PROTEIN 1; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ABCC5 PROTEIN, HUMAN; DNA; DNA BINDING PROTEIN; ERCC2 PROTEIN, HUMAN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XPA PROTEIN, HUMAN; XRCC1 PROTEIN;

ARTICLE; ASPIRATION BIOPSY; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MULTIPLE REGRESSION; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STANDARDIZATION; STATISTICAL MODEL; VALIDATION PROCESS; BIOLOGICAL MODEL; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; REPRODUCIBILITY; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DNA; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, GENETIC; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 26844514889     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-4-18     Document Type: Article

References (53)

1. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998, 34:1535-1542.
2. Dijt F, Fitchinger-Schepman AM, Berends F, Reedijk J: Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988, 48:6058-6062.
3. Zamble DB, Lippard SJ: Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995, 20:435-439.
4. States JC, Reed E: Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplifications. Cancer Lett 1996, 108:233-237.
5. Ferry KV, Fink D, Johnson SW, Hamilton TC, Howell SB: Quantitation of platinum-DNA adduct repair in mismatch repair deficient and proficient human colorectal cancer cell lines using an in vitro DNA repair assay [abstract]. Proc Am Assoc Cancer Res 1997, 38:359.
6. Jordan P, Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000, 57:1229-1235.
7. Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 2001, 478:23-43.
8. Berger W, Elbling L, Hauptmann E, Micksche M: Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 1997, 73:84-93.
9. Borst P, Kool M, Evers R: Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Cancer Biol 1997, 8:205-213.
10. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SPC, Deeley RG, Gerlach JH: Expression of multidrug resistance proteinrelated genes in lung cancer: correlation with drug response. Clin Cancer Res 1999, 5:673-680.
11. Berger W, Elbling L, Micksche M: Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000, 88:293-300.
12. Borst P, Evers R, Kool M, Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Nat Cancer Inst 2000, 92:1295-1302.
13. Oguri T, Isobe T, Suzuki T, Nishio K, Fujiwara Y, Katoh O, Yamakido M: Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 2000, 86:95-100.
14. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
15. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
16. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000, 24:236-244.
17. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, Kitahara O, Zembutsu H, Yanagawa R, Hirata K, Takagi T, Nakamura Y: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res 2001, 61:6474-6479.
18. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y: Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002, 62:518-527.
19. Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Respir Cell Mol Biol 1998, 19:6-17.
20. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP: Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996, 56:206-209.
21. DeMuth JP, Jackson CM, Weaver DA, Crawford EL, Durzinsky DS, Durham SJ, Zaher A, Phillips ER, Khuder SA, Willey JC: The gene expression index c-myc x E2F1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am J Respir Cell Mol Biol 1998, 19:18-24.
22. Crawford EL, Khuder SA, Durham SJ, Frampton M, Utell M, Thilly WG, Weaver DA, Ferencak WJ, Jennings CA, Hammersley JR, Olson DA, Willey JC: Normal bronchial epithelial cell expression of glutathione transferase P1, glutathione transferase M3, and glutathione peroxidase is low in subjects with bronchogenic carcinoma. Cancer Res 2000, 60:1609-1618.
23. Rots JG, Willey JC, Jansen G, Van Zantwijk CH, Noordhuis P, DeMuth JP, Kuiper E, Veerman AJ, Pieters R, Peters GJ: mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia 2000, 14:2166-2175.
24. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94:703-708.
25. Asahina H, Kuraoka I, Shirakawa M, Morita EH, Miura N, Miyamoto I, Ohtsuka E, Okada Y, Tanaka K: The XPA protein is a zinc metalloprotein with an ability to recognize various kinds of DNA damage. Mutat Res DNA Repair 1994, 315:229-237.
26. Li L, Peterson CA, Lu X, Legerski RJ: Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair. Mol Cell Biol 1995, 15:1993-1998.
27. Mu D, Park CH, Matsunaga T, Hsu DS, Reardon JT, Sancar A: Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem 1995, 270:2415-2418.
28. Reed E: Anticancer drugs: platinum analogs. In Principles and Practice of Oncology Edited by: Devita VT Jr, Hellman S, Rosenberg SA. Philadelphia, PA: Lippincott; 1993:390-399.
29. Mu D, Hsu DS, Sancar A: Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996, 271:8285-8294.
30. Schaeffer L, Moncollin V, Roy R, Staub A, Mezzina M, Sarasin A, Weeda G, Hoeijmakers JH, Egly JM: The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J 1994, 13:2388-2392.
31. Drapkin R, Reardon JT, Ansari A, Huang JC, Zawel L, Ahn K, Sancar A, Reinberg D: Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature 1994, 368:769-772.
32. Wang Z, Svejstrup JQ, Feaver WJ, Wu X, Kornberg RD, Friedberg EC: Transcription factor b (TFIIH) is required during nucleotide- excision repair in yeast. Nature 1994, 368:74-76.
33. Prakash S, Sung P, Prakash L: DNA repair genes and proteins of Saccharomyces cerevisiae. Annu Rev Genet 1993, 27:33-70.
34. Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrinin AM, Egly JM: Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nature Genet 1998, 20:184-188.
35. Yen L, Woo A, Christopoulopoulos G, Batist G, Panasci L, Roy R, Mitra S, Alaoui-Jamili MA: Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Mutation Research 1995, 337:179-189.
36. Damia G, Guidi G, D'Incalci M: Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. European Journal of Cancer 1998, 34:1783-1788.
37. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. Journal of the National Cancer Institute 1992, 84:1512-1517.
38. Hoeijmakers JHJ: Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
39. Wood RD, Mitchell M, Sgouros J, Lindahl T: Human DNA Repair Genes. Science 2001, 291:1284-1289.
40. Sancar A, Lindsey-Boltz LA, Ünsal-KaÇmaz K, Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85.
41. Zhang X, Xiaoping M, Liang G, Hao B, Wang Y, Tan W, Li Y, Guo Y, He F, Wei Q, Lin D: Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005, 65:722-726.
42. Audebert M, Salles B, Calsou P: Involvement of Poly (ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004, 279:55117-55126.
43. Chomczynski P: A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993, 15:536-537.
44. Willey JC, Coy E, Brolly C, Utell MJ, Frampton MW, Hammersley J, Thilly WG, Olson D, Cairns K: Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. Am J Respir Cell Mol Biol 1996, 14:262-271.
45. Apostolakos MJ, Schuermann WH, Frampton MW, Utell MJ, Willey JC: Measurement of gene expression by multiplex competitive polymerase chain reaction. Anal Biochem 1993, 213:277-284.
46. Willey JC, Coy EL, Frampton MW, Torres A, Apostolakos MJ, Hoehn G, Schuermann WH, Thilly WG, Olson DE, Hammersley JR, Crespi CL, Utell MJ: Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and non-smokers. Am J Respir Cell Mol Biol 1997, 17:114-124.
47. Celi FS, Zenilman ME, Shuldiner AR: A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Research 1993, 21:1047.
48. Crawford EL, Peters GJ, Noordhuis P, Rots MG, Vondracek M, Grafström RC, Lieuallen K, Lennon G, Zahorchak RJ, Georgeson MJ, Wali A, Lechner JF, Fan PS, Kahaleh MB, Khuder SA, Warner KA, Weaver DA, Willey JC: Reproducible gene expression measurement among multiple laboratories obtained in a blinded study using Standardized RT (StaRT)-PCR. Molecular Diagnosis 2001, 6:217-225.
49. Willey JC, Crawford EL, Knight CA, Warner KA, Motten CR, Herness Peters E, Zahorchak RJ, Graves TG, Bergman JR, Weaver DA, Vondracek M, Grafström RC: Use of standardized mixtures of internal standards in quantitative RT-PCR to ensure quality control and develop a standardized gene expression database. In A-Z of Quantitative PCR Edited by: Bustin SA. International University Line, La Jolla, CA; 2004:545-576.
50. Willey JC, Crawford EL, Knight CR, Warner KA, Motten CA, Herness EA, Zahorchak RJ, Graves TG: Standardized RT-PCR and the standardized expression measurement center. Methods Mol Biol 2004, 258:13-41.
51. Pagliarulo V, George B, Beil SJ, Groshen S, Laird PW, Cai J, Willey J, Cote RJ, Datar RH: Sensitivity and reproducibility of standardized- competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer 2004, 3:5.
52. Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MCL, Hanna W, Wittwer CT, Arun S, Lyon E: Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn 2003, 184-90:.
53. Gilliland G, Perrin S, Blanchard K, Bunn HF: Analysis of cytokine mRNA and DNA: Detection and quantification by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87:2725-2729.